2024

Suh M, Mitchell M, Hooda N, Bylsma LC, Cohen SS. 2024. The effects of dairy consumption on vaccine immune response and immunoglobulins: A systematic literature review. Int J Nutr 8(1):1–25; doi: 10.14302/issn.2379-7835.ijn-24-4938.

View Abstract

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; doi :10.1016/j.annonc.2023.10.262.

View Abstract

2023

Movva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. PLoS One 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

View Abstract

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303. ISPOR EU 2023.

View Abstract

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579. ISPOR EU 2023.

View Abstract

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734. ISPOR EU 2023.

View Abstract

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125. ISPOR EU 2023.

View Abstract

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547. ISPOR EU 2023.

View Abstract

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658. ISPOR EU 2023.

View Abstract

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309. AMP 2023 Annual Meeting & Expo.

View Abstract